Published in PLoS Clin Trials on May 25, 2007
Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV | NCT00122486
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS (2010) 4.20
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr (2010) 3.58
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One (2008) 3.45
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother (2010) 2.41
No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One (2013) 2.25
HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A (2010) 2.25
The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One (2008) 2.23
What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Ann Intern Med (2012) 2.19
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest (2008) 2.12
Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis (2010) 2.07
Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr (2010) 2.01
Transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis (2011) 1.98
From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS (2013) 1.97
Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep (2010) 1.90
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis (2012) 1.80
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
Heterogeneity in host HIV susceptibility as a potential contributor to recent HIV prevalence declines in Africa. AIDS (2009) 1.63
Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: a mixed methods study. PLoS One (2012) 1.44
Targeting Trojan Horse leukocytes for HIV prevention. AIDS (2010) 1.40
State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr (2012) 1.37
Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc (2010) 1.35
Empowering the people: development of an HIV peer education model for low literacy rural communities in India. Hum Resour Health (2008) 1.28
Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health (2010) 1.25
Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. J Acquir Immune Defic Syndr (2010) 1.24
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (2016) 1.20
The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One (2008) 1.06
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. AIDS Behav (2015) 1.03
HIV prevention by oral preexposure prophylaxis. Cold Spring Harb Perspect Med (2012) 1.03
Advances in HIV prevention for serodiscordant couples. Curr HIV/AIDS Rep (2014) 1.02
The Promise of Antiretrovirals for HIV Prevention. Curr Infect Dis Rep (2012) 1.02
Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clin Infect Dis (2010) 1.02
Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care STDS (2014) 1.02
Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation. Curr HIV/AIDS Rep (2010) 1.01
A systematic review of the quality of trials evaluating biomedical HIV prevention interventions shows that many lack power. HIV Clin Trials (2010) 0.98
High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2014) 0.97
Inclusion of trans women in pre-exposure prophylaxis trials: a review. AIDS Care (2014) 0.96
Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: balancing methodological rigor and research ethics. Soc Sci Med (2013) 0.96
Pre-exposure prophylaxis of HIV. Indian J Sex Transm Dis (2011) 0.94
Pregnancy and contraceptive use among women participating in an HIV prevention trial in Tanzania. Sex Transm Infect (2012) 0.94
Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.92
Preconception care: delivery strategies and packages for care. Reprod Health (2014) 0.92
Implications of HIV PrEP trials results. AIDS Res Hum Retroviruses (2010) 0.92
A preemptive strike against HIV. Nat Med (2009) 0.91
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial. J Acquir Immune Defic Syndr (2015) 0.90
Antiretroviral therapy for prevention of HIV infection: new clues from an animal model. PLoS Med (2008) 0.90
Unintended pregnancy among HIV positive couples receiving integrated HIV counseling, testing, and family planning services in Zambia. PLoS One (2013) 0.88
Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence - a narrative review. HIV AIDS (Auckl) (2015) 0.87
Preconception care: preventing and treating infections. Reprod Health (2014) 0.87
Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis (2011) 0.86
Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. Expert Opin Drug Saf (2015) 0.85
Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010. AIDS Behav (2015) 0.84
Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications. Curr HIV/AIDS Rep (2011) 0.83
Antiretrovirals to prevent HIV infection: pre- and postexposure prophylaxis. Curr Infect Dis Rep (2008) 0.83
The Art of HIV Elimination: Past and Present Science. J AIDS Clin Res (2015) 0.82
A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs (2012) 0.82
Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States. Infect Dis Rep (2011) 0.81
Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial. PLoS One (2013) 0.81
Interim data monitoring to enroll higher-risk participants in HIV prevention trials. BMC Med Res Methodol (2009) 0.81
Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials. J Acquir Immune Defic Syndr (2016) 0.80
Biomedical approaches to HIV prevention. Alcohol Res Health (2010) 0.78
HIV pre-exposure prophylaxis (PrEP)--a quantitative ethics appraisal. PLoS One (2011) 0.78
Antiretroviral-based HIV prevention strategies for women. Expert Rev Anti Infect Ther (2010) 0.78
The use of preexposure treatments for HIV prophylaxis. HIV AIDS (Auckl) (2012) 0.78
Role of the pharmacist in pre-exposure chemoprophylaxis (PrEP) therapy for HIV prevention. Pharm Pract (Granada) (2009) 0.78
HIV PrEP Trials: The Road to Success. Clin Investig (Lond) (2013) 0.77
Cultural conundrums: the ethics of epidemiology and the problems of population in implementing pre-exposure prophylaxis. Dev World Bioeth (2013) 0.76
Chemoprophylaxis of Tropical Infectious Diseases. Pharmaceuticals (Basel) (2010) 0.75
The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. J Acquir Immune Defic Syndr (2016) 0.75
Randomized controlled trials of HIV/AIDS prevention and treatment in Africa: results from the Cochrane HIV/AIDS Specialized Register. PLoS One (2011) 0.75
Oral PrEP for HIV prevention. It works. J Virus Erad (2015) 0.75
Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. Drug Saf (2017) 0.75
Delivering PrEP to pregnant and breastfeeding women in sub-Saharan africa: The implementation science frontier. AIDS (2017) 0.75
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science (1995) 9.48
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med (2006) 8.35
A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med (1997) 7.11
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis (2006) 5.24
A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med (1998) 4.35
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr (2004) 3.86
Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis (2001) 3.47
Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS (2004) 3.46
Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res (1987) 3.46
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther (1999) 2.85
Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2002) 2.71
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother (2002) 2.21
Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis (2006) 2.06
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev (2003) 1.91
Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev (2007) 1.67
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics (2005) 1.62
Tenofovir disoproxil fumarate. Clin Infect Dis (2003) 1.25
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol (2004) 1.18
Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology (2003) 1.00
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS (2003) 0.96
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health (2004) 12.00
Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep (2005) 8.91
RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell (2007) 8.71
Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet (2009) 6.80
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med (2008) 6.00
Magnesium sulfate tocolysis: time to quit. Obstet Gynecol (2006) 5.11
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One (2008) 3.45
Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis (2008) 3.31
The Good Clinical Practice guideline: a bronze standard for clinical research. Lancet (2005) 2.81
The safety of adult male circumcision in HIV-infected and uninfected men in Rakai, Uganda. PLoS Med (2008) 2.79
Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res (2011) 2.45
SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One (2007) 2.41
Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One (2008) 2.09
The time has come for common ground on preventing sexual transmission of HIV. Lancet (2004) 1.95
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One (2011) 1.84
Pregnancy in effectiveness trials of HIV prevention agents. Sex Transm Dis (2007) 1.79
Monitoring and assessment of wetlands using Earth Observation: the GlobWetland project. J Environ Manage (2008) 1.74
Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis (2002) 1.68
Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. Chest (2004) 1.63
Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav (2010) 1.60
Invited commentary: consequential(ist) epidemiology: let's seize the day. Am J Epidemiol (2013) 1.60
The multiple layers of prevention science research. Am J Prev Med (2005) 1.57
Sexual satisfaction of women partners of circumcised men in a randomized trial of male circumcision in Rakai, Uganda. BJU Int (2009) 1.54
Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep (2013) 1.49
Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics. Nature (2006) 1.48
The prevalence of incontinence in people with cognitive impairment or dementia living at home: a systematic review. Neurourol Urodyn (2012) 1.47
Performance of a rapid and simple HIV testing algorithm in a multicenter phase III microbicide clinical trial. Clin Vaccine Immunol (2011) 1.47
The contribution of physician assistants in primary care: a systematic review. BMC Health Serv Res (2013) 1.44
Defining and assessing evidence for the effectiveness of technical assistance in furthering global health. Glob Public Health (2012) 1.43
HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS (2010) 1.41
Reproductive choices for women with HIV. Bull World Health Organ (2009) 1.38
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2014) 1.36
Waiting times for carotid endarterectomy in UK: observational study. BMJ (2009) 1.34
Is this woman perimenopausal? JAMA (2003) 1.31
Family planning and HIV: strange bedfellows no longer. AIDS (2009) 1.28
Voluntary medical male circumcision: an HIV prevention priority for PEPFAR. J Acquir Immune Defic Syndr (2012) 1.28
Anthrax postexposure prophylaxis in postal workers, Connecticut, 2001. Emerg Infect Dis (2002) 1.27
Multilevel and kin selection in a connected world. Nature (2010) 1.26
Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS (2007) 1.26
Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care (2012) 1.26
Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet (2009) 1.23
How frequently do young people with potential cancer symptoms present in primary care? Br J Gen Pract (2011) 1.18
Are condoms the answer to rising rates of non-HIV sexually transmitted infections? Yes. BMJ (2008) 1.17
Sexual risk behaviours and HIV-1 prevalence among urban men who have sex with men in Cape Town, South Africa. Sex Health (2010) 1.16
Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg (2011) 1.15
Reaching the underserved: family planning for women with HIV. Stud Fam Plann (2010) 1.14
Acceptability of PrEP for HIV prevention among women at high risk for HIV. J Womens Health (Larchmt) (2010) 1.14
Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDS (2013) 1.14
Risk factors for obstetric fistula in the Far North Province of Cameroon. Int J Gynaecol Obstet (2009) 1.13
Assessing the contribution of prescribing in primary care by nurses and professionals allied to medicine: a systematic review of literature. BMC Health Serv Res (2011) 1.13
Reducing the burden of sexually transmitted infections in resource-limited settings: the role of improved diagnostics. Nature (2006) 1.13
Temozolomide for high grade glioma. Cochrane Database Syst Rev (2008) 1.11
Condoms and sexually-transmitted infections. N Engl J Med (2006) 1.09
Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review. AIDS (2009) 1.08
Hormonal contraception and HIV: an unanswered question. Lancet Infect Dis (2011) 1.07
Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr (2014) 1.05
Awareness of HPV and cervical cancer prevention among Cameroonian healthcare workers. BMC Womens Health (2011) 1.02
Validation of a job aid to rule out pregnancy among family planning clients in Nicaragua. Rev Panam Salud Publica (2008) 1.02
Notes from the Field: Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention - Eastern and Southern Africa, 2012-2015. MMWR Morb Mortal Wkly Rep (2016) 1.02
Bioterrorism-related inhalational anthrax in an elderly woman, Connecticut, 2001. Emerg Infect Dis (2003) 1.02
Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev (2011) 1.02
Contraception is the best kept secret for prevention of mother-to-child HIV transmission. Bull World Health Organ (2008) 1.01
The role of family planning in elimination of new pediatric HIV infection. Curr Opin HIV AIDS (2013) 1.01
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr (2014) 1.00
Integration of family planning into HIV services: a synthesis of recent evidence. AIDS (2013) 0.99
One Health approach to identify research needs in bovine and human babesioses: workshop report. Parasit Vectors (2010) 0.99
Epidemic Intelligence Service investigations of respiratory illness, 1946-2005. Am J Epidemiol (2011) 0.98
Use of topical sRAGE in diabetic wounds increases neovascularization and granulation tissue formation. Ann Plast Surg (2004) 0.97
Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception (2010) 0.97
Understanding the relevance of global health to North Carolina. N C Med J (2011) 0.97
Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy. AIDS (2015) 0.97
Bioterrorism-related anthrax surveillance, Connecticut, September-December, 2001. Emerg Infect Dis (2002) 0.96
Use of DNA fingerprinting to investigate a multiyear, multistate tuberculosis outbreak. Emerg Infect Dis (2002) 0.95
An exploration of the relationship between youth assets and engagement in risky sexual behaviors. J Adolesc Health (2004) 0.94
Menstrual bleeding patterns following levonorgestrel emergency contraception. Contraception (2006) 0.93
Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial. Obstet Gynecol (2003) 0.93
HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin Immunol (2006) 0.92
20 µg versus >20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev (2013) 0.89
HPTN 052 and the future of HIV treatment and prevention. Lancet (2011) 0.89
Chemotherapeutic wafers for High Grade Glioma. Cochrane Database Syst Rev (2008) 0.88
In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs? PLoS Med (2009) 0.88
The condom forgiveness factor: the positive spin. Sex Transm Dis (2002) 0.86
Decreased condom breakage and slippage rates after counseling men at a sexually transmitted infection clinic in Jamaica. Contraception (2007) 0.86
Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis (2011) 0.86
Coverage, context and targeted prevention: optimising our impact. Sex Transm Infect (2012) 0.86
Family history is a predictor for appendicitis in adults in the emergency department. West J Emerg Med (2012) 0.85
Internucleotide movements during formation of 16 S rRNA-rRNA photocrosslinks and their connection to the 30 S subunit conformational dynamics. J Mol Biol (2005) 0.85
Safety of quinacrine contraceptive pellets: results from 10-year follow-up in Vietnam. Contraception (2008) 0.85
A survey of tuberculosis clinic provision in England and Wales. Public Health (2008) 0.84
A pilot study of proximal strength training in Charcot-Marie-Tooth disease. J Peripher Nerv Syst (2014) 0.84
Steroid hormones for contraception in men. Cochrane Database Syst Rev (2012) 0.84
Contraceptive effectiveness of two insertions of quinacrine: results from 10-year follow-up in Vietnam. Contraception (2008) 0.84
Contraception and prevention of HIV infection. JAMA (2006) 0.83
Women's ability to self-screen for contraindications to combined oral contraceptive pills in Tanzanian drug shops. Int J Gynaecol Obstet (2013) 0.83